Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $106 to $108.
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $106 to $108.